🏥 MASTER SHEET: HOSPITAL & CLINICAL PHARMACY
UPSC Drug Inspector 2026 (CDSCO) | Subject 10 | Final Exam Notes
This masterclass offers a high-density review of Hospital & Clinical Pharmacy, essential for UPSC Drug Inspector 2026. It meticulously covers drug distribution, rational drug use, therapeutic drug monitoring, and pharmacovigilance. Key topics include cold chain management, patient counselling, clinical pharmacy services, and emergency poison management, highlighting regulatory aspects and patient safety for comprehensive preparation.
🎯 Exam Strategy: This subject is highly clinical and regulatory. CDSCO questions focus on drug distribution systems, rational drug use, TDM, pharmacovigilance, cold chain, and hospital pharmacy management. Expect scenario-based questions, match-the-following on drug categories, and direct one-liners on WHO/GOI guidelines.
SECTION 1: DRUG DISTRIBUTION SYSTEMS IN HOSPITALS
1.1 Types of Drug Distribution
| System | Description | Advantages | Disadvantages |
|---|
| Individual Prescription Order System | Each patient gets medication as per individual prescription | Simple, no ward stock | Time-consuming, high workload |
| Floor Stock System | Common drugs stocked on wards; nurses dispense | Quick access, reduced pharmacy workload | Risk of misuse, pilferage, no pharmacist check |
| Unit Dose System | Medications packaged in single doses; dispensed per patient per dose | Reduced errors, better control, pharmacist review | High initial cost, labor-intensive |
| Ward/Unit-Based System | Medications supplied to wards in bulk; nurses administer | Efficient for large hospitals | Less control, potential for errors |
| Satellite Pharmacy System | Mini-pharmacies located near patient care areas | Immediate availability, clinical pharmacist involvement | High staffing cost |
| Centralized Intravenous Admixture Service (CIVAS) | All IV medications prepared in central sterile facility | Sterility assurance, reduced contamination, cost-effective | Requires specialized infrastructure |
1.2 Unit Dose System (Most Important)
Definition: Medications are packaged and dispensed in single-unit doses for individual patients
Key Features:
- Each dose is individually labeled with drug name, strength, lot number, expiration date
- Barcode scanning for verification
- Pharmacist reviews every order before dispensing
- Medication carts delivered to patient floors
Benefits:
- Reduces medication errors by 50-70%
- Eliminates drug waste
- Improves inventory control
- Enables charge capture per patient
WHO Recommendation: Preferred system for hospitals
1.3 Automated Dispensing Systems
| Technology | Function |
|---|
| Automated Dispensing Cabinets (ADCs) | Computer-controlled cabinets on nursing units; require PIN/biometric access |
| Robotic Dispensing Systems | Robots pick and package medications from bulk stock |
| Carousel Systems | Rotating shelves for efficient storage and retrieval |
| Barcode Medication Administration (BCMA) | Scan patient wristband + medication barcode before administration |
SECTION 2: PRESCRIPTION HANDLING & DISPENSING
2.1 Parts of a Valid Prescription
- Prescriber Information
- Name, Qualification, Registration
- Address, Contact, Signature
- Patient Information
- Name, Age, Sex, Weight
- Address, Allergies
- Date of Prescription
- Mandatory; prescriptions valid for limited period (usually 3-6 months depending on drug class)
- Superscription (Rx symbol)
- ℞ = "Recipe" = "Take thou"
- Inscription (Drug Details)
- Drug name (generic preferred)
- Strength, Dosage form
- Quantity
- Subscription (Directions to Dispenser)
- "M.f.t. pulv." = Make into powder
- "M.f.t. caps." = Make capsules
- Signatura (Directions to Patient)
- Dose, frequency, route, duration
- "t.i.d." = three times daily
- "a.c." = before meals
- "p.c." = after meals
- "h.s." = at bedtime
- "p.r.n." = as needed
- "stat" = immediately
- Refill Information
- Number of refills permitted
2.2 Common Latin Abbreviations (Must Memorize)
🎯 Must Memorize: Essential Latin abbreviations for prescription interpretation.
| Abbreviation | Latin | English |
|---|
| a.c. | ante cibum | Before meals |
| p.c. | post cibum | After meals |
| b.i.d. | bis in die | Twice daily |
| t.i.d. | ter in die | Three times daily |
| q.i.d. | quarter in die | Four times daily |
| q.d. | quaque die | Every day |
| q.h. | quaque hora | Every hour |
| q.4h. | quaque 4 hora | Every 4 hours |
| q.d.s. | quater die sumendus | To be taken four times a day |
| o.d. | omni die | Every day |
| o.n. | omni nocte | Every night |
| h.s. | hora somni | At bedtime |
| stat | statim | Immediately |
| p.r.n. | pro re nata | As needed |
| ad lib. | ad libitum | As desired |
| N.B. | nota bene | Note well |
| N.B.M. | nil by mouth | Nothing by mouth |
| p.o. | per os | By mouth |
| i.m. | intramuscular | Into the muscle |
| i.v. | intravenous | Into the vein |
| s.c./s.q. | sub cutis | Subcutaneous |
| N.R. | non repetatur | Do not repeat |
| S.O.S. | si opus sit | If necessary |
2.3 Prescription Validation (Pharmacist's Duty)
Pharmacist's Duty: Critical checks before dispensing.
Before Dispensing, Check:
- ✓ Legality — Is prescriber registered and authorized?
- ✓ Completeness — All parts filled?
- ✓ Rationality — Is the drug appropriate for the condition?
- ✓ Dosage — Correct for age, weight, renal/hepatic function?
- ✓ Drug Interactions — Any contraindicated combinations?
- ✓ Allergies — Patient has known allergies?
- ✓ Duplication — Same drug/class prescribed twice?
- ✓ Abbreviations — Clear and unambiguous?
- ✓ Expiry — Is prescription within valid period?
- ✓ Controlled substances — Special regulations followed?
SECTION 3: THERAPEUTIC DRUG MONITORING (TDM)
3.1 Principles
Definition: Measurement of drug concentrations in biological fluids to optimize therapy
- Rationale: Correlation between dose and plasma concentration is poor for many drugs due to pharmacokinetic variability
- Goal: Maintain drug concentration within therapeutic window (between MEC and MTC)
3.2 Drugs Requiring TDM (Narrow Therapeutic Index)
| Drug Class | Examples | Therapeutic Range | Toxic Level |
|---|
| Antiepileptics | Phenytoin, Carbamazepine, Valproic acid, Phenobarbital | 10–20 µg/mL (phenytoin) | >20 µg/mL |
| Antiarrhythmics | Digoxin, Lidocaine, Procainamide, Amiodarone | 0.5–2.0 ng/mL (digoxin) | >2.5 ng/mL |
| Antibiotics | Aminoglycosides (Gentamicin, Amikacin), Vancomycin | Peak: 5–10 µg/mL (gentamicin) | >12 µg/mL |
| Immunosuppressants | Cyclosporine, Tacrolimus, Mycophenolate, Sirolimus | 100–400 ng/mL (cyclosporine) | >400 ng/mL |
| Bronchodilators | Theophylline | 10–20 µg/mL | >20 µg/mL |
| Antipsychotics | Lithium, Clozapine | 0.6–1.2 mEq/L (lithium) | >1.5 mEq/L |
| Anticoagulants | Warfarin (INR monitoring) | INR 2.0–3.0 | >4.0 |
3.3 TDM Protocol
- Determine NEED for TDM
↓ - Collect sample at CORRECT TIME
- Trough (Cmin): Just before next dose (most common)
- Peak (Cmax): 30 min after IV bolus / 1-2h after IM/oral
- Steady-state: After 4-5 half-lives of chronic dosing
↓ - Use APPROPRIATE SAMPLE
- Serum/Plasma (most common)
- Whole blood (cyclosporine, tacrolimus — in RBCs)
- Saliva (correlates with free drug concentration)
↓ - Use VALIDATED analytical method
- HPLC, LC-MS/MS, Immunoassay (EMIT, FPIA)
↓ - INTERPRET results
- Consider patient condition, timing, compliance
- Adjust dose using pharmacokinetic principles
3.4 Key Pharmacokinetic Parameters in TDM
| Parameter | Symbol | Significance |
|---|
| Minimum Effective Concentration | MEC | Below this = therapeutic failure |
| Minimum Toxic Concentration | MTC | Above this = toxicity likely |
| Therapeutic Window | MTC – MEC | Range for safe and effective therapy |
| Trough Concentration | Cmin | Lowest concentration (just before next dose) |
| Peak Concentration | Cmax | Highest concentration (after absorption) |
| Area Under Curve | AUC | Total drug exposure over time |
| Clearance | CL | Volume of blood cleared of drug per unit time |
SECTION 4: PHARMACOVIGILANCE (PV)
4.1 Definition & Scope
Definition: Science and activities relating to detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems
WHO Definition (1960s): "The science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other drug-related problem"
- Scope: Covers all medicines (allopathic, traditional, complementary, blood products, biologicals, vaccines)
4.2 Types of Adverse Drug Reactions (ADRs)
| Classification | Description | Examples |
|---|
| Type A (Augmented) | Dose-related; predictable from pharmacology | Hypoglycemia with insulin, bleeding with warfarin |
| Type B (Bizarre) | Non-dose-related; unpredictable, often immune-mediated | Anaphylaxis with penicillin, Stevens-Johnson syndrome |
| Type C (Chronic) | Dose and time-related; due to long-term use | Osteoporosis with corticosteroids, tardive dyskinesia with antipsychotics |
| Type D (Delayed) | Dose-related; delayed onset | Teratogenesis (thalidomide), carcinogenesis |
| Type E (End of use) | Withdrawal reactions | Opioid withdrawal, benzodiazepine withdrawal |
| Type F (Failure) | Unexpected failure of therapy | Antibiotic resistance, contraceptive failure |
4.3 ADR Reporting Systems
A. WHO-UMC (Uppsala Monitoring Centre)
- International drug monitoring program
- VigiBase: Global database of ADR reports
- Member countries (including India) submit reports
B. PvPI — Pharmacovigilance Programme of India
- Launched: July 2010
- Coordinated by: Indian Pharmacopoeia Commission (IPC), Ghaziabad
- National Coordination Centre (NCC): IPC
- ADR Reporting Forms:
- Form I: For healthcare professionals (doctors, nurses, pharmacists)
- Form II: For consumers/patients
- Helpline: 1800-180-3024 (toll-free)
- Website: www.ipc.gov.in
C. CDSCO Reporting
- Mandatory for pharmaceutical companies (MAH — Marketing Authorization Holders)
- PSUR (Periodic Safety Update Report) submission required
- SUSAR (Suspected Unexpected Serious Adverse Reaction) reporting within 15 days
4.4 Causality Assessment (WHO-UMC Scale)
| Category | Definition |
|---|
| Certain | Event with plausible time relationship; cannot be explained by disease/other drugs; confirmed by rechallenge |
| Probable/Likely | Reasonable time sequence; unlikely to be attributed to disease/other drugs; not confirmed by rechallenge |
| Possible | Reasonable time sequence; could also be explained by disease/other drugs |
| Unlikely | Time sequence improbable; disease/other drugs provide plausible explanation |
| Conditional/Unclassified | More data needed for assessment |
| Unassessable/Unclassifiable | Insufficient/contradictory information |
4.5 Severity Assessment
| Category | Definition |
|---|
| Mild | No change in therapy; no antidote required |
| Moderate | Requires change in therapy; hospitalization may be needed |
| Severe | Potentially life-threatening; requires specific treatment |
| Serious (Regulatory Definition) | Results in death, life-threatening, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent impairment |
4.6 Key Pharmacovigilance Documents
| Document | Purpose | Frequency |
|---|
| ICSR (Individual Case Safety Report) | Single ADR report | As received |
| PSUR (Periodic Safety Update Report) | Cumulative safety data | Every 6 months for first 2 years, then annually |
| PBRER (Periodic Benefit-Risk Evaluation Report) | Benefit-risk balance | Same as PSUR |
| RMP (Risk Management Plan) | Proactive risk minimization | At approval and updates |
| DSUR (Development Safety Update Report) | Safety during clinical trials | Annually |
SECTION 5: RATIONAL DRUG USE (RDU)
5.1 WHO Definition
"Rational use of drugs requires that patients receive medications appropriate to their clinical needs, in doses that meet their own individual requirements, for an adequate period of time, and at the lowest cost to them and their community."
5.2 Five Rights of Medication Administration
- Right Patient
- Right Drug
- Right Dose
- Right Route
- Right Time
Extended Rights: Right documentation, Right reason, Right response, Right to refuse, Right education
5.3 Irrational Drug Use Practices
| Practice | Example | Consequence |
|---|
| Overuse | Antibiotics for viral infections | Resistance, side effects |
| Underuse | Incomplete TB treatment | Treatment failure, MDR-TB |
| Misuse | Wrong drug for condition | Therapeutic failure |
| Polypharmacy | >5 drugs in elderly | Drug interactions, ADRs |
| Use of injections when oral suffices | IV antibiotics for UTI | Increased cost, infection risk |
| Self-medication | Buying antibiotics OTC | Resistance, delayed diagnosis |
| Use of brand names instead of generics | Prescribing expensive brands | Increased cost |
5.4 Strategies to Promote RDU
| Strategy | Description |
|---|
| Essential Medicines List (EML) | WHO/Country-specific list of most cost-effective medicines |
| Standard Treatment Guidelines (STGs) | Evidence-based treatment protocols for common conditions |
| Drug Formulary | Approved list of drugs for hospital/institution |
| Drug & Therapeutics Committee (DTC) | Hospital committee overseeing drug use policies |
| Academic Detailing | Educational outreach by pharmacists to prescribers |
| Drug Utilization Review (DUR) | Retrospective review of prescribing patterns |
| Prescription Audit | Regular review of prescriptions for rationality |
| Public Education | Awareness campaigns for patients |
5.5 WHO Model List of Essential Medicines
- First published: 1977
- Updated: Every 2 years
- Current list: ~460 medicines (core + complementary)
- India's National List of Essential Medicines (NLEM):
- First published: 1996
- Current: NLEM 2022 (384 medicines)
- Price control under DPCO 2013 based on NLEM
SECTION 6: DRUG INFORMATION SERVICES
6.1 Types of Drug Information Queries
| Category | Examples |
|---|
| Product Availability | "Is drug X available in India?" |
| Identification | "What is this tablet with marking ABC?" |
| Dosage & Administration | "What is the pediatric dose of amoxicillin?" |
| Adverse Effects | "Can drug X cause liver damage?" |
| Drug Interactions | "Can warfarin be given with aspirin?" |
| Use in Pregnancy/Lactation | "Is metformin safe in pregnancy?" |
| Compatibility/Stability | "Can drug X and Y be mixed in same IV bag?" |
| Pharmacoeconomics | "What is the cost-effective alternative?" |
| Therapeutic Alternatives | "What can replace drug X if unavailable?" |
6.2 Sources of Drug Information
Primary Sources (Original Research)
- Clinical trials, RCTs
- Case reports
- Original research articles in journals
Secondary Sources (Indexed/Abstracted)
- PubMed/MEDLINE
- EMBASE
- Cochrane Library
- International Pharmaceutical Abstracts (IPA)
Tertiary Sources (Reviewed/Synthesized)
- Martindale: The Complete Drug Reference
- AHFS Drug Information
- British National Formulary (BNF)
- Indian National Formulary
- Drug Facts and Comparisons
- Meyler's Side Effects of Drugs
- Goodman & Gilman's Pharmacological Basis of Therapeutics
Online Databases
- Micromedex
- Lexicomp
- UpToDate
- Clinical Pharmacology
- Medscape
- DailyMed (FDA)
6.3 Systematic Approach to Answering Queries (Systematic vs. Random)
- Step 1: RECEIVE & CLARIFY
- Understand the real question
- Determine urgency (stat vs. routine)
- Identify who is asking and why
↓
- Step 2: SEARCH & RETRIEVE
- Select appropriate resources
- Search systematically (primary → secondary → tertiary)
↓ - Step 3: EVALUATE
- Assess quality of evidence
- Check for bias, conflicts of interest
- Consider applicability to specific patient
↓ - Step 4: FORMULATE RESPONSE
- Provide concise, evidence-based answer
- Include references
- Add clinical context
↓ - Step 5: DOCUMENT & FOLLOW-UP
- Record query and response
- Follow up if needed
SECTION 7: COLD CHAIN MANAGEMENT
7.1 Definition
Cold Chain: An uninterrupted series of storage and distribution activities which maintain a given temperature range (usually 2–8°C for vaccines)
- Purpose: Preserve potency of temperature-sensitive products (vaccines, insulin, blood products, certain antibiotics)
7.2 Temperature Requirements
| Product Category | Temperature Range | Examples |
|---|
| Standard Cold Chain | 2–8°C | Most vaccines, insulin, interferons |
| Frozen | -15 to -25°C | Some vaccines (MMR, Varicella, OPV) |
| Ultra-Low | -60 to -80°C | mRNA vaccines (Pfizer COVID-19) |
| Controlled Room Temperature | 15–25°C | Most oral medications |
| Blood Products | 2–6°C | Whole blood, RBCs |
| Platelets | 20–24°C (with agitation) | Platelet concentrates |
7.3 Vaccine Cold Chain (India — UIP)
Universal Immunization Programme (UIP) Vaccines:
- BCG, OPV, Hepatitis B, Pentavalent (DPT+HepB+Hib), Rotavirus, PCV, IPV, MR, DPT booster, TT
Cold Chain Equipment (India):
| Equipment | Temperature | Capacity | Location |
|---|
| ILR (Ice-Lined Refrigerator) | 2–8°C | 140–300L | District/Block PHC |
| DF (Deep Freezer) | -15 to -25°C | 140–300L | District/Block |
| Cold Box | 2–8°C | 20–50L | Transport |
| Vaccine Carrier | 2–8°C | 1.7–8L | Outreach sessions |
| Ice Pack | Maintains cold | — | Inside carriers |
7.4 Vaccine Vial Monitor (VVM)
- Purpose: Time-temperature indicator on vaccine vials
- Mechanism: Heat-sensitive square that changes color with cumulative heat exposure
- Reading:
- Inner square lighter than outer ring: VVM is GOOD, vaccine can be used
- Inner square matches or darker than outer ring: VVM is BAD, vaccine DISCARDED
- VVM Types: VVM2, VVM7, VVM14, VVM30 (numbers indicate days of stability at 37°C)
7.5 Shake Test for Frozen Vaccines
- Purpose: Detect if freeze-sensitive vaccines have been frozen
- Method: Shake vial vigorously, let stand; observe sedimentation rate
- Frozen vaccine: Sedimentation is rapid (forms clumps)
- Never frozen: Sedimentation is slow and smooth
- Freeze-sensitive vaccines: HepB, DPT, TT, pentavalent, liquid Hib
7.6 WHO "30-Days Open Vial Policy"
- Multi-dose vials of certain vaccines can be used for up to 28 days after opening if:
- Stored at correct temperature (2–8°C)
- Not expired
- Not contaminated
- Handled aseptically
- Applies to: OPV, DPT, TT, HepB, pentavalent, liquid Hib
- Does NOT apply to: BCG, Measles, MR, JE (single-dose or special preservatives)
SECTION 8: PATIENT COUNSELLING
8.1 Definition & Importance
Definition: Providing medication information to patients to ensure safe and effective use
- Goal: Improve adherence, reduce errors, enhance therapeutic outcomes
- WHO: Pharmacist counseling is a core component of pharmaceutical care
8.2 Counseling Steps (Pharmacist's Approach)
- Step 1: INTRODUCE yourself and establish rapport
↓ - Step 2: CONFIRM patient identity and medication
↓ - Step 3: EXPLAIN what the medication is for
↓ - Step 4: DESCRIBE how to take it (dose, frequency, route, duration)
↓ - Step 5: DISCUSS special instructions (food, storage, missed dose)
↓ - Step 6: WARN about side effects and what to do
↓ - Step 7: CHECK for drug interactions and allergies
↓ - Step 8: ASSESS understanding (teach-back method)
↓ - Step 9: PROVIDE written information if needed
↓ - Step 10: OFFER to answer questions and follow up
8.3 Counseling Points for Common Drug Categories
| Drug Category | Key Counseling Points |
|---|
| Antibiotics | Complete full course; don't share; take with food if GI upset; report rash |
| Antihypertensives | Don't stop abruptly; monitor BP; some cause cough (ACEI), ankle edema (CCB) |
| Oral Hypoglycemics | Take with meals; carry sugar for hypoglycemia; monitor blood glucose |
| Warfarin | Consistent vitamin K intake; report bleeding; regular INR monitoring |
| Inhalers | Demonstrate technique; rinse mouth after steroid inhalers |
| Eye Drops | Don't touch tip to eye; wait 5 min between different drops |
| NSAIDs | Take with food; avoid alcohol; watch for GI bleeding |
| Statins | Take at bedtime; report muscle pain; avoid grapefruit |
8.4 Special Populations Counseling
| Population | Considerations |
|---|
| Pediatrics | Use proper measuring devices; palatability; storage safety |
| Geriatrics | Simplify regimen; large print labels; medication organizers |
| Pregnant Women | Teratogenicity; folic acid; avoid NSAIDs in 3rd trimester |
| Lactating Mothers | Drug excretion in milk; timing of doses |
| Renal Impairment | Dose adjustment; nephrotoxic drug avoidance |
| Hepatic Impairment | Hepatotoxic drug avoidance; monitor LFTs |
SECTION 9: CLINICAL PHARMACY SERVICES
9.1 Definition & Evolution
Clinical Pharmacy: Area of pharmacy concerned with science and practice of rational medication use
- Evolution: From product-oriented → patient-oriented → pharmaceutical care
Pharmaceutical Care (Hepler & Strand, 1990): "Responsible provision of drug therapy for the purpose of achieving definite outcomes that improve a patient's quality of life"
9.2 Roles of Clinical Pharmacist
| Role | Description |
|---|
| Medication Therapy Management (MTM) | Comprehensive review of all patient medications |
| Anticoagulation Monitoring | Warfarin/DOAC dosing based on INR/clinical status |
| Antimicrobial Stewardship | Optimize antibiotic use, reduce resistance |
| TDM Services | Monitor and adjust doses of narrow TI drugs |
| Pain Management | Opioid rotation, adjuvant therapy |
| Nutrition Support | TPN formulation and monitoring |
| Heart Failure Management | ACEI, beta-blocker, diuretic optimization |
| Transitions of Care | Medication reconciliation at admission/discharge |
9.3 Medication Reconciliation
Definition: Process of comparing a patient's medication orders to all medications the patient has been taking
- Critical Points: Admission, transfer between units, discharge
- Goal: Avoid omissions, duplications, dosing errors, drug interactions
- JCAHO (Joint Commission): Medication reconciliation is a National Patient Safety Goal
SECTION 10: HOSPITAL PHARMACY ADMINISTRATION
10.1 Pharmacy & Therapeutics Committee (P&T / DTC)
- Composition: Physicians, pharmacists, nurses, administrators, quality assurance
- Functions:
- Develop and maintain hospital formulary
- Evaluate new drugs for formulary addition
- Develop medication use policies and protocols
- Review ADRs and medication errors
- Oversee antimicrobial stewardship
- Monitor drug utilization patterns
10.2 Hospital Formulary
Definition: List of medications approved for use in the hospital
- Types:
- Closed Formulary: Only formulary drugs available; non-formulary requires special approval
- Open Formulary: Most drugs available; formulary guides preferred choices
- India: Most government hospitals follow EML-based formularies
10.3 Inventory Management
| Method | Description |
|---|
| ABC Analysis | Classify inventory by value: A (high value, 10% items, 70% value), B (moderate), C (low value, 70% items, 10% value) |
| VED Analysis | Classify by criticality: Vital, Essential, Desirable |
| ABC-VED Matrix | Combines both for prioritization |
| EOQ (Economic Order Quantity) | Optimal order quantity minimizing total inventory costs |
| FIFO (First In First Out) | Use oldest stock first |
| FEFO (First Expired First Out) | Use earliest expiring stock first (preferred for pharmaceuticals) |
| Just-In-Time (JIT) | Order as needed to reduce inventory holding |
10.4 Quality Assurance in Hospital Pharmacy
| Aspect | Measures |
|---|
| Dispensing Accuracy | Regular audits; error reporting system |
| Sterility Assurance | Media fill tests; environmental monitoring |
| Storage Conditions | Temperature logs; humidity monitoring |
| Expiry Management | FEFO system; monthly expiry checks |
| Documentation | Complete prescription records; TDM logs |
| Compounding Quality | USP <797>/<800> compliance (if applicable) |
SECTION 11: EMERGENCY & POISON MANAGEMENT
11.1 Emergency Drug Box / Crash Cart
Essential Contents:
- Adrenaline (Epinephrine) 1:1000 and 1:10,000
- Atropine sulfate
- Amiodarone / Lidocaine
- Dopamine / Dobutamine
- Sodium bicarbonate
- Calcium gluconate
- Hydrocortisone / Dexamethasone
- Diazepam / Lorazepam
- Dextrose 50%
- Saline / Dextrose normal saline
- Aspirin (chewable)
- Nitroglycerin (sublingual)
- Furosemide
- Naloxone
11.2 Common Poisonings & Antidotes (High-Yield)
🎯 High-Yield: Crucial Antidotes to memorize for exams.
| Poison/Toxin | Antidote | Mechanism |
|---|
| Paracetamol overdose | N-Acetylcysteine (NAC) | Replenishes glutathione; prevents liver damage |
| Opioids | Naloxone | Competitive opioid receptor antagonist |
| Benzodiazepines | Flumazenil | Competitive BZD receptor antagonist |
| Organophosphates | Atropine + Pralidoxime (2-PAM) | Atropine blocks muscarinic effects; 2-PAM reactivates AChE |
| Warfarin/Superwarfarin | Vitamin K1 (Phytonadione) | Replenishes vitamin K-dependent clotting factors |
| Heparin | Protamine sulfate | Forms stable complex with heparin |
| Iron | Deferoxamine | Chelates free iron |
| Lead | EDTA / Dimercaprol / Succimer | Chelating agents |
| Arsenic/Mercury | Dimercaprol (BAL) / Succimer (DMSA) | Chelating agents |
| Cyanide | Hydroxocobalamin / Sodium thiosulfate | Binds cyanide to form cyanocobalamin / converts to thiocyanate |
| Methanol/Ethylene glycol | Fomepizole / Ethanol | Inhibits alcohol dehydrogenase |
| Beta-blockers | Glucagon | Bypasses blocked beta-receptors via cAMP |
| Calcium channel blockers | Calcium gluconate / High-dose insulin + glucose | Competitive antagonism / metabolic support |
| Digoxin | Digoxin-specific antibody fragments (Digibind/DigiFab) | Binds and neutralizes digoxin |
| Tricyclic antidepressants | Sodium bicarbonate | Alkalinization reduces QRS widening |
| Acetylsalicylic acid (Aspirin) | Sodium bicarbonate | Alkaline diuresis enhances elimination |
11.3 Decontamination Methods
| Method | Indication | Contraindication |
|---|
| Activated Charcoal | Most oral poisons within 1-2 hours | Unprotected airway, caustics, hydrocarbons |
| Gastric Lavage | Life-threatening poison within 1 hour | Caustics, hydrocarbons, unprotected airway |
| Whole Bowel Irrigation | Sustained-release, iron, lithium, body packers | Bowel obstruction, ileus |
| Cathartics | Enhance elimination (limited use) | Dehydration, electrolyte imbalance |
| Urine Alkalinization | Salicylates, phenobarbital | Renal failure, fluid overload |
| Hemodialysis | Lithium, methanol, ethylene glycol, salicylates, theophylline | Hemodynamic instability |
SECTION 12: QUICK REVISION TABLES
Table A: Drug Distribution Systems Comparison
| Feature | Floor Stock | Unit Dose | CIVAS |
|---|
| Error reduction | Low | High | High |
| Cost | Low | High initial | Moderate |
| Pharmacist involvement | Low | High | High |
| Inventory control | Poor | Excellent | Good |
| Best for | Small hospitals | Large hospitals | All hospitals with IV therapy |
Table B: TDM — Sample Timing
| Drug | Sample Type | Timing | Therapeutic Range |
|---|
| Gentamicin | Serum | Trough: just before next dose; Peak: 30 min after infusion end | Trough: <2 µg/mL; Peak: 5–10 µg/mL |
| Vancomycin | Serum | Trough: just before next dose | Trough: 10–20 µg/mL |
| Phenytoin | Serum | Trough (any time at steady state) | 10–20 µg/mL |
| Digoxin | Serum | Trough (≥6h post-dose) | 0.5–2.0 ng/mL |
| Cyclosporine | Whole blood | Trough (C0) or C2 (2h post-dose) | 100–400 ng/mL |
| Lithium | Serum | Trough (12h after evening dose) | 0.6–1.2 mEq/L |
Table C: Pharmacovigilance — Key Organizations
| Organization | Role | Location |
|---|
| WHO-UMC | Global drug monitoring | Uppsala, Sweden |
| IPC | NCC for PvPI | Ghaziabad, India |
| CDSCO | Regulatory authority | New Delhi, India |
| FDA (CDER) | US drug regulation | USA |
| EMA | EU drug regulation | Amsterdam, Netherlands |
Table D: Cold Chain Temperatures
| Product | Temperature | Monitoring |
|---|
| Most vaccines | 2–8°C | VVM, thermometer |
| OPV, MMR | -15 to -25°C | Thermometer |
| mRNA vaccines | -60 to -80°C | Digital logger |
| Blood (whole/RBC) | 2–6°C | Continuous monitor |
| Platelets | 20–24°C + agitation | Continuous monitor |
Table E: Essential Emergency Antidotes
| Antidote | Poison | Dose (Adult) |
|---|
| N-Acetylcysteine | Paracetamol | 150 mg/kg IV over 1h, then 50 mg/kg over 4h, then 100 mg/kg over 16h |
| Naloxone | Opioids | 0.4–2 mg IV/IM; repeat every 2–3 min |
| Atropine | Organophosphates | 2 mg IV every 10 min until atropinization |
| Pralidoxime (2-PAM) | Organophosphates | 1–2 g IV over 15–30 min |
| Vitamin K1 | Warfarin | 2.5–25 mg PO/IV (higher for superwarfarin) |
| Protamine | Heparin | 1 mg per 100 units heparin |
| Digibind | Digoxin | Based on ingested dose or serum level |
| Flumazenil | Benzodiazepines | 0.2 mg IV; repeat up to 1 mg |
📝 LAST-MINUTE EXAM CHECKLIST (Hospital & Clinical Pharmacy)
- Unit dose system vs. floor stock — advantages and disadvantages
- All Latin abbreviations (a.c., p.c., b.i.d., t.i.d., stat, p.r.n., etc.)
- TDM drugs and their therapeutic ranges (phenytoin, digoxin, gentamicin, vancomycin, lithium, cyclosporine)
- ADR classification: Type A (augmented) vs. Type B (bizarre) with examples
- PvPI: Launch year (2010), coordinating body (IPC), helpline number
- WHO-UMC causality assessment categories (Certain → Unassessable)
- Five rights of medication administration
- WHO definition of rational drug use
- Essential Medicines List — WHO and India (NLEM)
- Cold chain: 2–8°C for most vaccines; VVM reading; shake test
- Vaccine vial monitor (VVM) — when to discard
- 30-day open vial policy — which vaccines apply
- Patient counseling steps and key points for common drugs
- Medication reconciliation — when performed
- P&T Committee / DTC functions
- ABC and VED analysis in inventory management
- Emergency antidotes: NAC (paracetamol), naloxone (opioids), atropine+2PAM (organophosphates), vitamin K (warfarin), digibind (digoxin)
- Decontamination methods: activated charcoal, gastric lavage, whole bowel irrigation
